Phase II study of dose-dense doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/NEU-overexpressed/amplified breast cancer: Feasibility.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Jun 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Lapatinib (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel; Pegfilgrastim; Trastuzumab
Indications Breast cancer
Focus Therapeutic Use

06 Mar 2013 Additional lead trial center added as reported by ClinicalTrials.gov.
27 Jul 2010 Planned end date changed from 1 Mar 2009 to 1 Mar 2010 as reported by ClinicalTrials.gov.
13 Oct 2008 Status changed from recruiting to active, no longer recruiting, based on information from ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com